Free Trial
NASDAQ:IMCR

Immunocore (IMCR) Stock Price, News & Analysis

Immunocore logo
$30.10 -0.37 (-1.21%)
As of 04:00 PM Eastern

About Immunocore Stock (NASDAQ:IMCR)

Key Stats

Today's Range
$30.01
$30.76
50-Day Range
$24.53
$30.81
52-Week Range
$23.15
$62.74
Volume
127,223 shs
Average Volume
433,976 shs
Market Capitalization
$1.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.44
Consensus Rating
Hold

Company Overview

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Immunocore Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

IMCR MarketRank™: 

Immunocore scored higher than 61% of companies evaluated by MarketBeat, and ranked 809th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immunocore has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 6 buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Immunocore has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Immunocore's stock forecast and price target.
  • Earnings Growth

    Earnings for Immunocore are expected to decrease in the coming year, from ($0.94) to ($1.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immunocore is -31.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immunocore is -31.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immunocore has a P/B Ratio of 4.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Immunocore's valuation and earnings.
  • Percentage of Shares Shorted

    15.77% of the float of Immunocore has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunocore has a short interest ratio ("days to cover") of 25.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunocore has recently decreased by 4.95%, indicating that investor sentiment is improving.
  • Dividend Yield

    Immunocore does not currently pay a dividend.

  • Dividend Growth

    Immunocore does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.77% of the float of Immunocore has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunocore has a short interest ratio ("days to cover") of 25.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunocore has recently decreased by 4.95%, indicating that investor sentiment is improving.
  • News Sentiment

    Immunocore has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Immunocore this week, compared to 5 articles on an average week.
  • Search Interest

    Only 1 people have searched for IMCR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immunocore insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,994,085.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    10.40% of the stock of Immunocore is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immunocore's insider trading history.
Receive IMCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.

IMCR Stock News Headlines

Immunocore Holdings: A Name On My Watch List
J.P. Morgan Remains a Buy on Immunocore Holdings (IMCR)
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
Immunocore Holdings (IMCR) Gets a Buy from Needham
Immunocore price target lowered to $33 from $38 at Mizuho
See More Headlines

IMCR Stock Analysis - Frequently Asked Questions

Immunocore's stock was trading at $29.50 on January 1st, 2025. Since then, IMCR shares have increased by 2.8% and is now trading at $30.33.
View the best growth stocks for 2025 here
.

Immunocore Holdings plc (NASDAQ:IMCR) announced its quarterly earnings data on Wednesday, November, 6th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.50. The business's revenue for the quarter was up 23.7% on a year-over-year basis.

Immunocore (IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies acted as the underwriters for the IPO.

Immunocore's top institutional shareholders include Principal Financial Group Inc. (0.96%), Envestnet Asset Management Inc. (0.13%), Hennion & Walsh Asset Management Inc. (0.13%) and GAMMA Investing LLC (0.04%). Insiders that own company stock include Bros Advisors Lp Baker and Leger Tina Amber St.
View institutional ownership trends
.

Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunocore investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/06/2024
Today
4/30/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMCR
Fax
N/A
Employees
320
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$59.44
High Stock Price Target
$100.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+95.8%
Consensus Rating
Hold
Rating Score (0-4)
2.45
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-55,290,000.00
Pretax Margin
-18.14%

Debt

Sales & Book Value

Annual Sales
$310.20 million
Price / Cash Flow
N/A
Book Value
$7.42 per share
Price / Book
4.09

Miscellaneous

Free Float
45,480,000
Market Cap
$1.52 billion
Optionable
Optionable
Beta
0.75
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:IMCR) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners